INKT IPOs 3.83M* shares @$12.00: https://www.globenewswire.com/news-release/2021/10/15/2314718/0/en/MiNK-Therapeutics-Inc-Announces-Pricing-of-Initial-Public-Offering.html MiNK Therapeutics is a clinical stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases... The company is headquartered in New York, NY. *Assuming exercise of underwriter’s option.